Status: Path 1 of [Dialog Information Services via Mod

Status: Initializing TCP/IP using (UseTelnetProto 1 ServiceID pto-dialog)

Trying 31060000009999...Open

DIALOG INFORMATION SERVICES

PLEASE LOGON:

****** HHHHHHHH SSSSSSS?

Status: Signing onto Dialog

ENTER PASSWORD:

Welcome to DIALOG

Status: Connected

Dialog level 02.19.00D

Last logoff: 18aug03 15:32:11 Logon file001 20aug03 10:47:27

*** ANNOUNCEMENT ***

--File 654 - US published applications from March 15, 2001 to the present are now online. Please see HELP NEWS 654 for details.

--File 581 - The 2003 annual reload of Population Demographics is complete. Please see Help News581 for details.

--File 990 - NewsRoom now contains February 2003 to current records. File 992 - NewsRoom 2003 archive has been newly created and contains records from January 2003. The oldest months's records roll out of File 990 and into File 992 on the first weekend of each month. To search all 2003 records BEGIN 990, 992, or B NEWS2003, a new OneSearch category.

-- Connect Time joins DialUnits as pricing options on Dialog.

See HELP CONNECT for information.

--SourceOne patents are now delivered to your email inbox as PDF replacing TIFF delivery. See HELP SOURCE1 for more information.

-- Important news for public and academic libraries. See HELP LIBRARY for more information.

-- Important Notice to Freelance Authors --See HELP FREELANCE for more information

NEW FILES RELEASED

***World News Connection (File 985)

***Dialog NewsRoom - 2003 Archive (File 992)

***TRADEMARKSCAN-Czech Republic (File 680)

***TRADEMARKSCAN-Hungary (File 681)
***TRADEMARKSCAN-Poland (File 682)

UPDATING RESUMED

RELOADED

***Population Demographics - (File 581)

***CLAIMS Citation (Files 220-222)

REMOVED

```
>>> Enter BEGIN HOMEBASE for Dialog Announcements <<<
            >>> of new databases, price changes, etc.
 KWIC is set to 50.
 HILIGHT set on as '*'
 * * * * See HELP NEWS 225 for information on new search prefixes
 and display codes
                                                       ***

***

***

***

***

***

***

***

***

***

***

***

**

***

***

***

***

***

***

***

***

***

***

***

***

**

***

***

***

***

***

***

***

***

***

***

***

***

**

***

***

***

***

***

***

***

***

***

***

***

***

**

***

***

***

***

***

***

***

***

***

***

***

***

**

***

***

***

***

***

***

***

***

***

***

***

***

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**

**
File 1:ERIC 1966-2003/Aug 13
               (c) format only 2003 The Dialog Corporation
               Set Items Description
               Cost is in DialUnits
 ?b 155
                 20aug03 10:47:31 User259876 Session D535.1
                            $0.34 0.096 DialUnits File1
            $0.34 Estimated cost File1
           $0.01 TELNET
            $0.35 Estimated cost this search
            $0.35 Estimated total session cost 0.096 DialUnits
File 155:MEDLINE(R) 1966-2003/Aug W3
                 (c) format only 2003 The Dialog Corp.
*File 155: Medline has been reloaded and accession numbers have
changed. Please see HELP NEWS 155.
              Set Items Description
        (particle (w) mediated) (s) (bombardment or polynucleotide or DNA)
                        41452 PARTICLE
                       307466 MEDIATED
                            5697 BOMBARDMENT
                          3760 POLYNUCLEOTIDE
                       697150 DNA
                      70 (PARTICLE (W) MEDIATED) (S) (BOMBARDMENT OR
              S1
                                          POLYNUCLEOTIDE OR DNA)
?s s1 and review
                                70 S1
                       317118 REVIEW
                          7 S1 AND REVIEW
?s s1 and (viral (w) vector)
                                70 S1
                       294096 VIRAL
                       48434 VECTOR
617 VIRAL(W) VECTOR
0 S1 AND (VIRAL (W) VECTOR)
              S3
?s s1 and (minimal (w) promoter)
                                70 S1
                       102800 MINIMAL
                       93012 PROMOTER
                            1011 MINIMAL (W) PROMOTER
              S4
                               0 S1 AND (MINIMAL (W) PROMOTER)
?s s1 and (enhancerless (w) promoter)
                                70 S1
                               100 ENHANCERLESS
                         93012 PROMOTER
                                   8 ENHANCERLESS (W) PROMOTER
             S5
                                   0 S1 AND (ENHANCERLESS (W) PROMOTER)
2 	 s2/3, k/all
```

' 2/3,K/1

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

15201682 22783105 PMID: 12901567

Needle-free epidermal powder immunization.

Chen Dexiang; Maa Yuh-Fun; Haynes Joel R

PowderJect Vaccines Inc., Madison, WI 53711, USA. dexiang chen@powderject.com

Expert Rev Vaccines (England) Oct 2002, 1 (3) p265-76, ISSN 1476-0584 Journal Code: 101155475

Document type: Journal Article

Languages: ENGLISH
Main Citation Owner: NLM
Record type: In Process

... potentially safer alternatives to needle injection and promises increased efficacy in the prevention and/or therapy of infectious diseases, allergic disorders and cancer. In this *review*, we will cover advances in needle-free skin vaccination technologies and their potential applications to disease prevention and therapy. Emphasis will be placed on epidermal powder immunization and *particle*-*mediated* ('gene gun') *DNA* immunization, which use similar mechanical devices to deliver protein and *DNA* vaccines, respectively, into the viable epidermis.

2/3,K/2

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

14913780 22313145 PMID: 12426488

Gene therapy in soft tissue reconstruction.

Hoeller Daniela; Petrie Nicola; Yao Feng; Eriksson Elof

Division of Plastic Surgery, Harvard Medical School, Brigham and Women's Hospital, Boston, Mass 02115, USA.

Cells, tissues, organs (Switzerland) 2002, 172 (2) p118-25, ISSN 1422-6405 Journal Code: 100883360

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

vehicles and techniques that have been developed to deliver therapeutic genes into cells, such as viral vectors and physical/chemical gene delivery methods including naked *DNA* and *particle*-*mediated* gene transfer, the microseeding technique and the application of lipids. Furthermore we *review* the potential utility of gene therapy from the perspective of a reconstructive surgeon. Several tissues will be discussed, particularly muscle, tendon, nerve, bone, skin and...

2/3, K/3

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

14787973 22322084 PMID: 12435047

Particle-*mediated* *DNA* vaccination of mice, monkeys and men: looking beyond the dogma.

Payne Lendon G; Fuller Deborah H; Haynes Joel R

Address PowderJect Vaccines Inc, Madison, WI 53711, USA. lendon-payne@powderject.com

Current opinion in molecular therapeutics (England) Oct 2002, 4 (5)

p459-66, ISSN 1464-8431 Journal Code: 100891485 Document type: Journal Article; Review, Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM Record type: Completed

Particle-*mediated* *DNA* vaccination of mice, monk ys and men: looking beyond the dogma.

... data. To some degree, this has happened at least twice in the relatively new area of DNA immunization. Early data seemed to indicate firstly that *particle*-*mediated* epidermal *DNA* immunization induced predominantly Th2-type cellular immune responses, and secondly that *DNA* immunization was not very successful in humans. This *review* highlights the current body of data showing that *particle*-*mediated* *DNA* immunization is highly effective in the induction Th1-type responses and is an efficient method for inducing immune responses in humans.

2/3,K/4

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

14607563 22177701 PMID: 12189722

Improvement of nonviral gene therapy by Epstein-Barr virus (EBV)-based plasmid vectors.

Mazda O

Department of Microbiology, Kyoto Prefectural University of Medicine, Kamikyo, Kyoto 602-8566, Japan. mazda@basic.kpu-m.ac.jp

Current gene therapy (Netherlands) Sep 2002, 2 (3) p379-92, ISSN 1566-5232 Journal Code: 101125446

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM Record type: Completed

The nonviral gene transfer technologies include naked *DNA* administration, electrical or *particle*-*mediated* transfer of naked *DNA*, and administration of *DNA*-synthetic macromolecule complex vectors. Each method has its advantage, such as low immunogenicity, inexpensiveness, ease in handling, etc., but the common disadvantage is that the...

...EBNA1 gene and oriP element that enable high transfer efficiency, strong transgene expression and long term maintenance of the expression. In the current article, I *review* recent preclinical gene therapy studies with the EBV plasmid vectors conducted against various diseases. For gene therapy against malignancies, drastic tumor suppression was achieved by...

2/3, K/5

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

11214805 98091727 PMID: 9429892

DNA cancer vaccines: a gene gun approach.

Mahvi D M; Sheehy M J; Yang N S

Department of Surgery, University of Wisconsin School of Medicine, Madison, USA.

Immunology and cell biology (AUSTRALIA) Oct 1997, 75 (5) p456-60, ISSN 0818-9641 Journal Code: 8706300

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM Record type: Completed

... include both ex vivo and in vivo gene transfer to tumour and/or non-tumour cells, using both viral and non-viral vectors. The transferred *DNA* has varied widely as well, including genomic or cDNA encoding tumour-associated or oncofoetal antigens, cytokines, histocompatibility molecules, and costimulatory molecules. Several of these approaches have been applied in human clinical trials. This *review* summarizes those approaches, then compares and evaluates various methods using cytokine *DNA* in conjunction with autologous tumour cells, with particular emphasis

on *particle*-*mediated gene transfer via a gene gun. Pally, prospects and needs for further development are discussed.

2/3, K/6

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

10813667 97103542 PMID: 8947913

Developing particle-mediated gene-transfer technology for research into gene therapy of cancer.

Yang N S; Sun W H; McCabe D

Middleton, 53562, Cancer Gene Therapy, Auragen Inc., USA. nsyang@agracetus.com

Molecular medicine today (ENGLAND) Nov 1996, 2 (11) p476-81, ISSN Journal Code: 9508560 1357-4310

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM Record type: Completed

... pursued by researchers in molecular medicine. New gene transfer technologies are rapidly developing and some have proved to be powerful tools for medical research. This *review* discusses the development and application of *particle*-*mediated* gene transfer technology experimental systems and its potential clinical utilities.

2/3, K/7

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

10753667 97103542 PMID: 8947913

Developing particle-mediated gene-transfer technology for research into gene therapy of cancer.

Yang N S; Sun W H; McCabe D

Gene Cancer Therapy, Auragen Inc., Middleton, WI 53562, nsyang@agracetus.com

Molecular medicine today (ENGLAND) Nov 1996, 2 (11) p476-81, Journal Code: 9508560

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM \ Record type: Completed

... pursued by researchers in molecular medicine. New gene transfer technologies are rapidly developing and some have proved to be powerful tools for medical research. This *review* discusses the development and *particle*-*mediated* application of gene transfer technology in experimental systems and its potential clinical utilities. ?ds

```
Set
        Items
                Description
S1
           70
                (PARTICLE (W) MEDIATED) (S) (BOMBARDMENT OR POLYNUCLEOTIDE
             OR DNA)
S2
            7
                S1 AND REVIEW
S3
                S1 AND (VIRAL (W) VECTOR)
            0
S4
            0
                S1 AND (MINIMAL (W) PROMOTER)
S5
                S1 AND (ENHANCERLESS (W) PROMOTER)
?logoff
       20aug03 10:51:15 User259876 Session D535.2
            $2.43
                   0.759 DialUnits File155
               $1.47 7 Type(s) in Format 3
            $1.47 7 Types
```

\$3.90 Estimated cost File155

\$0.92 TELNET

\$4.82 Estimated cost this search

Status: Signed Off. (4 minutes)